ASCEND Therapeutics, Inc. Presents Results Of Phase 2 Clinical Trial For Cyclic Breast Pain; Company's Transdermal 4-OHT Therapy Was Well Tolerated And Reduced Breast Pain In Clinical Trial
10/19/2005 5:10:14 PM
HERNDON, Va.--(BUSINESS WIRE)--May 11, 2005--ASCEND Therapeutics, a leading research and development company of pharmaceutical transdermal therapies for the treatment of chronic conditions, today announced that researchers presented findings regarding the company's 4-hydroxytamoxifen (4-OHT) gel during the 53rd Annual Clinical Meeting of the American College of Obstetricians and Gynecologists (ACOG) at the Moscone Center in San Francisco.
A poster presentation at ACOG offered data on the safety and efficacy of ASCEND Therapeutics' 4-OHT gel in patients with menstrual-cycle related mastalgia. The Phase 2 study, which was a placebo-controlled, double-blind, dose-ranging, and randomized study, indicated that the investigational transdermal 4-OHT gel, if approved by the FDA, may represent a new way to treat cyclic breast pain, also called cyclic mastalgia.
comments powered by